HRP20120916T1 - DERIVATI 6H-DIBENZO[b,e]OKSEPINA KAO NESTEROIDNI ANTAGONISTI MINERALOKORTIKOIDNOG RECEPTORA - Google Patents

DERIVATI 6H-DIBENZO[b,e]OKSEPINA KAO NESTEROIDNI ANTAGONISTI MINERALOKORTIKOIDNOG RECEPTORA Download PDF

Info

Publication number
HRP20120916T1
HRP20120916T1 HRP20120916AT HRP20120916T HRP20120916T1 HR P20120916 T1 HRP20120916 T1 HR P20120916T1 HR P20120916A T HRP20120916A T HR P20120916AT HR P20120916 T HRP20120916 T HR P20120916T HR P20120916 T1 HRP20120916 T1 HR P20120916T1
Authority
HR
Croatia
Prior art keywords
compound
pharmaceutically acceptable
salt
dibenz0
oxepine
Prior art date
Application number
HRP20120916AT
Other languages
English (en)
Croatian (hr)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120916(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20120916T1 publication Critical patent/HRP20120916T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20120916AT 2007-12-19 2008-12-09 DERIVATI 6H-DIBENZO[b,e]OKSEPINA KAO NESTEROIDNI ANTAGONISTI MINERALOKORTIKOIDNOG RECEPTORA HRP20120916T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20120916T1 true HRP20120916T1 (hr) 2012-12-31

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120916AT HRP20120916T1 (hr) 2007-12-19 2008-12-09 DERIVATI 6H-DIBENZO[b,e]OKSEPINA KAO NESTEROIDNI ANTAGONISTI MINERALOKORTIKOIDNOG RECEPTORA

Country Status (33)

Country Link
US (1) US7994164B2 (OSRAM)
EP (2) EP2235007B1 (OSRAM)
JP (1) JP5562866B2 (OSRAM)
KR (1) KR101254382B1 (OSRAM)
CN (1) CN101903377B (OSRAM)
AR (1) AR069554A1 (OSRAM)
AU (1) AU2008343524B2 (OSRAM)
BR (1) BRPI0820805A2 (OSRAM)
CA (1) CA2710409C (OSRAM)
CL (1) CL2008003600A1 (OSRAM)
CO (1) CO6300953A2 (OSRAM)
DK (1) DK2235007T3 (OSRAM)
DO (1) DOP2010000185A (OSRAM)
EA (1) EA017668B1 (OSRAM)
EC (2) ECSP10010266A (OSRAM)
ES (2) ES2459318T3 (OSRAM)
GT (1) GT201000179A (OSRAM)
HR (1) HRP20120916T1 (OSRAM)
IL (1) IL206353A (OSRAM)
MA (1) MA31910B1 (OSRAM)
MX (1) MX2010006911A (OSRAM)
MY (1) MY150474A (OSRAM)
NZ (1) NZ586300A (OSRAM)
PE (1) PE20091057A1 (OSRAM)
PL (1) PL2235007T3 (OSRAM)
PT (1) PT2235007E (OSRAM)
RS (1) RS52594B (OSRAM)
SI (1) SI2235007T1 (OSRAM)
TN (1) TN2010000292A1 (OSRAM)
TW (1) TWI431010B (OSRAM)
UA (1) UA100131C2 (OSRAM)
WO (1) WO2009085584A1 (OSRAM)
ZA (1) ZA201004257B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
BRPI0821342A2 (pt) 2007-12-19 2019-09-24 Boehringer Ingelheim Int inibidores da polimerase viral
AU2010222902B2 (en) * 2009-03-12 2013-04-18 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
WO2011157798A1 (en) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
UA111696C2 (uk) 2013-05-02 2016-05-25 Пфайзер Інк. Похідні імідазотриазину як інгібітори рde10
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
CA2953655C (en) 2014-06-30 2020-05-12 Astrazeneca Ab Benzoxazinone amides as mineralocorticoid receptor modulators
US20170246166A1 (en) * 2014-11-21 2017-08-31 Eli Lilly And Company 1,2-benzothiazole compounds for the treatment of kidney disorders
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
UA123464C2 (uk) * 2016-09-24 2021-04-07 Кейбіпі Байосайєнсіз Ко., Лтд. Фармацевтична композиція, яка містить антагоніст мінералокортикоїдних рецепторів, та її застосування
JP7697961B2 (ja) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
ATE320431T1 (de) * 2001-11-21 2006-04-15 Millennium Pharm Inc Chemokine rezeptor antagonisten und methoden zu deren anwendung
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7803814B2 (en) * 2003-12-19 2010-09-28 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
US20060116382A1 (en) 2004-11-10 2006-06-01 Wenqing Yao Lactam compounds and their use as pharmaceuticals
BRPI0717937A2 (pt) 2006-10-31 2013-12-03 Pfizer Prod Inc Compostos de pirazona como antagonistas do receptor mineralocorticóide
JP2010522732A (ja) 2007-03-29 2010-07-08 ナームローゼ・フエンノートチヤツプ・オルガノン 鉱質コルチコイド受容体アンタゴニスト
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
US20100292233A1 (en) 2008-01-25 2010-11-18 Arena Pharmaceuticals, Inc. Dihydro-1h-pyrrolo[1,2-a]indol-1-yl carboxylic acid derivatives which act as s1p1 agonists
AU2010222902B2 (en) 2009-03-12 2013-04-18 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
ZA201004257B (en) 2011-11-30
EP2537845B1 (en) 2014-03-19
DOP2010000185A (es) 2010-09-15
TN2010000292A1 (en) 2011-11-11
KR101254382B1 (ko) 2013-04-15
JP2011507868A (ja) 2011-03-10
RS52594B (sr) 2013-04-30
EP2235007A1 (en) 2010-10-06
EP2235007B1 (en) 2012-10-31
PL2235007T3 (pl) 2013-03-29
DK2235007T3 (da) 2012-12-17
US7994164B2 (en) 2011-08-09
CA2710409C (en) 2012-11-06
AR069554A1 (es) 2010-02-03
TW200930721A (en) 2009-07-16
MY150474A (en) 2014-01-30
ES2396605T3 (es) 2013-02-22
WO2009085584A1 (en) 2009-07-09
JP5562866B2 (ja) 2014-07-30
AU2008343524A1 (en) 2009-07-09
CA2710409A1 (en) 2009-07-09
CL2008003600A1 (es) 2010-02-19
HK1144284A1 (en) 2011-02-11
EP2537845A1 (en) 2012-12-26
EA201070762A1 (ru) 2010-12-30
US20090163472A1 (en) 2009-06-25
CN101903377A (zh) 2010-12-01
GT201000179A (es) 2012-04-16
MA31910B1 (fr) 2010-12-01
ES2459318T3 (es) 2014-05-09
NZ586300A (en) 2012-06-29
KR20100082866A (ko) 2010-07-20
ECSP10010266A (es) 2010-07-30
CN101903377B (zh) 2014-07-09
TWI431010B (zh) 2014-03-21
SI2235007T1 (sl) 2013-01-31
BRPI0820805A2 (pt) 2015-06-16
IL206353A0 (en) 2010-12-30
PT2235007E (pt) 2013-01-22
AU2008343524B2 (en) 2012-03-08
CO6300953A2 (es) 2011-07-21
MX2010006911A (es) 2010-10-05
IL206353A (en) 2014-06-30
ECSP12012048A (es) 2012-08-31
PE20091057A1 (es) 2009-07-20
EA017668B1 (ru) 2013-02-28
UA100131C2 (uk) 2012-11-26

Similar Documents

Publication Publication Date Title
HRP20120916T1 (hr) DERIVATI 6H-DIBENZO[b,e]OKSEPINA KAO NESTEROIDNI ANTAGONISTI MINERALOKORTIKOIDNOG RECEPTORA
IL189499A (en) Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
WO2008048981A3 (en) Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007146758A3 (en) Novel mch receptor antagonists
WO2008018827A8 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
MX2009001534A (es) Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva.
JP2013543896A5 (OSRAM)
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
DK2238110T3 (da) 5.6-bisaryl-2-pyridin-carboxamid-derivater, fremstilling heraf og terapeutisk anvendelse heraf som urotensin II-receptorantagonister
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
AR066168A1 (es) Formulaciones galenicas de compuestos organicos
WO2007124757A3 (en) Use of escitalopram for improving cognition
RU2009111378A (ru) Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5
JP2019536816A5 (OSRAM)
JP2008513510A5 (OSRAM)
FI3506900T3 (fi) Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
CN110023286A (zh) 作为ccr2/ccr5受体拮抗剂的联苯化合物
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты
CL2012002341A1 (es) Composición farmacéutica sólida oral que comprende ramipril y besilato de amlodipino; procedimiento de preparación; uso en el tratamiento de hipertensión arterial y prevención de infarto de miocardio, trastornos cerebrovasculares y cardíacos e insuficiencia renal.